SCHEMBL20964609

SCHEMBL20964609

Cc1noc(C)c1CSc1ncccc1C(=O)N1CCN(c2ccccn2)CC1

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 12/20 0.61
TSHR P16473 4/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
LMNA P02545 3/20 0.61
HSD17B10 Q99714 8/20 0.53
KDM4E B2RXH2 5/20 0.53
MAPT P10636 1/20 0.53
HPGD P15428 4/20 0.52
CYP2C19 P33261 2/20 0.52
MAPK1 P28482 1/20 0.52
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP2C9 P11712 1/20 0.50
AR P10275 3/20 0.48
CYP3A4 P08684 1/20 0.48
GAA P10253 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20964706 0.90 SMN1; SMN2 (0.56) ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10
SCHEMBL20964654 0.90 ALDH1A1 (0.76) ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10
SCHEMBL20964621 0.89 SMN1; SMN2 (0.54) ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10
SCHEMBL20964554 0.87 SMN1; SMN2 (0.54) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL20964607 0.86 MAPT (0.53) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL20964632 0.85 SMN1; SMN2 (0.57) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL20964600 0.85 TSHR (0.56) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL20964660 0.85 SMN1; SMN2 (0.63) ALDH1A1TSHRSMN1; SMN2LMNAKDM4E
SCHEMBL20964635 0.84 ALDH1A1 (0.63) ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10
SCHEMBL20964627 0.84 LMNA (0.62) ALDH1A1TSHRSMN1; SMN2LMNAHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2020-12-01 US disclosed
US-20190127361-A1 Therapeutic Compounds RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-05-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190127361-A1 Therapeutic Compounds SDHA, SLC10A1, SERPINC1 ALDH1A1 141/4885TSHR 3423/4885SMN1; SMN2 263/4885
US-10851096-B2 Aryl and heteroaryl amides for use as anti-proliferative, anti-thrombotic, and anti-viral agents SERPINC1, F12, RPL35 ALDH1A1 870/4885TSHR 2794/4885SMN1; SMN2 2477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.